Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
New Outcomes in Acute Graft-versus-Host Disease
Graft versus Host Disease
Read More
What`s New in Acute Graft-versus-Host Disease?
Advances in Steroid-Refractory Acute GVHD
Reducing Early Disease Progression in Follicular Lymphoma
Follicular Lymphoma
Addressing Unmet Needs in HER2-Positive Metastatic Breast Cancer
Breast Cancer
Advances in Metastatic Castration-Sensitive Prostate Cancer
Daratumumab as Frontline Treatment for Multiple Myeloma
Multiple Myeloma
Novel IL-2 Based Combinations for Bladder Cancer
Bladder Cancer
Real-World Data for Chemotherapy Treatment in Metastatic Triple-Negative Breast Cancer
Treatment Options for Stage III Unresectable NSCLC After Chemoradiotherapy
Lung Cancer
New Immunotherapeutic Agents Broaden Treatment Options for Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
PI3K Inhibitors in R/R Follicular Lymphoma
Treatment Options for Recurrent Metastatic Triple-Negative Breast Cancer
SIRT for Nonresectable CRC With Liver Metastases
Colorectal Cancer
Systemic Treatment of Metastatic Cutaneous Squamous Cell Carcinoma
Skin Cancer
Evolving NSCLC Treatment Paradigm
Upfront Therapy for mRCC
Kidney Cancer
NKTR-214 & Nivolumab: Synergistic Activity Across Tumor Types
General Cancer
Endocrine Therapy for HR+ Metastatic Breast Cancer
PARP Inhibitors in Ovarian Cancer
Treatment of Newly Diagnosed Advanced Kidney Cancer
Changing Treatment Landscape in Nonmetastatic CRPC
Prostate Cancer
Immunotherapy in Unresectable Locally Advanced NSCLC
Immunotherapy Use in Newly Diagnosed NSCLC
IMiD Sequencing in Multiple Myeloma